Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 81.07% is 47% above its 1-year average of 55.18%, near the high end of its 1-year range (0.00%–83.21%).
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 83.21%.
GROSS MARGIN
81.07%
GROSS MARGIN AVG TTM
N/A
GROSS MARGIN AVG 3Y
N/A
GROSS MARGIN AVG 5Y
N/A
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.38%
median of 692 covered companies
CURRENT VS SECTOR MEDIAN
+100.77%
vs the sector median at left
Mobia Medical, Inc. Common Stock
Market Cap
$310.71M
Gross Margin
81.07%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$304.72M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
25.00%
5Y Avg
13.20%
Market Cap
$297.62M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$321.20M
Gross Margin
77.81%
TTM Avg
88.91%
3Y Avg
85.13%
5Y Avg
50.71%
Market Cap
$291.48M
Gross Margin
49.14%
TTM Avg
49.09%
3Y Avg
45.86%
5Y Avg
49.48%
Market Cap
$291.19M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$288.54M
Gross Margin
73.68%
TTM Avg
36.84%
3Y Avg
49.00%
5Y Avg
66.00%
Market Cap
$287.63M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Mobia Medical, Inc. Common Stock (MOBI) | $310.71M | 81.07% | N/A | N/A | N/A |
| Benitec Biopharma Inc. (BNTC)vs › | $304.72M | 0.00% | 0.00% | 25.00% | 13.20% |
| CapsoVision, Inc. (CV)vs › | $320.21M | 50.88% | 53.58% | 54.49% | 54.49% |
| Larimar Therapeutics, Inc. (LRMR)vs › | $297.62M | 0.00% | 0.00% | 0.00% | 0.00% |
| C4 Therapeutics, Inc. (CCCC)vs › | $321.20M | 77.81% | 88.91% | 85.13% | 50.71% |
| Standard BioTools Inc. (LAB)vs › | $291.48M | 49.14% | 49.09% | 45.86% | 49.48% |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $291.19M | 0.00% | 0.00% | 0.00% | 0.00% |
| Abeona Therapeutics Inc. (ABEO)vs › | $288.54M | 73.68% | 36.84% | 49.00% | 66.00% |
| Indaptus Therapeutics, Inc. (INDP)vs › | $287.63M | 0.00% | 0.00% | 0.00% | 0.00% |
| Cabaletta Bio, Inc. (CABA)vs › | $334.69M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
81.1%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 83.21% |
| 2026-03-31 | 82.33% |
| 2025-12-31 | 0.00% |